Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (THALLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00578292
Recruitment Status : Terminated (Stem cell transplant was determined SOC for this disease (study is not relevant))
First Posted : December 21, 2007
Results First Posted : May 1, 2020
Last Update Posted : May 1, 2020
Sponsor:
Information provided by (Responsible Party):
Tami D. John, Baylor College of Medicine

Tracking Information
First Submitted Date  ICMJE December 19, 2007
First Posted Date  ICMJE December 21, 2007
Results First Submitted Date  ICMJE April 3, 2020
Results First Posted Date  ICMJE May 1, 2020
Last Update Posted Date May 1, 2020
Study Start Date  ICMJE February 2004
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 30, 2020)
  • Engraftment Rate After Transplant [ Time Frame: up to 30 days ]
    Engraftment is defined as an absolute neutrophil count (ANC) >500/microL x 3 days.
  • Number of Participants With Stable Mixed Hematopoietic Chimerism (HC) [ Time Frame: 1 year post-transplant ]
    Stable hematopoietic chimerism is defined as having 50-99 percent of donor cells.
  • Number of Participants With Transient Mixed Hematopoietic Chimerism (HC) [ Time Frame: 1 year post-transplant ]
    Transient mixed hematopoietic chimerism is defined as any mixed chimerism return to 100 percent donor.
  • Number of Participants With Infectious Complications [ Time Frame: up to day 100 ]
    All AEs and SAEs (including infections) will be collected for evaluation of infectious complications.
  • Hematopoietic Reconstitution [ Time Frame: 1 year post-transplant ]
    Hematopoietic: defined as transfusion independence.
  • Immune Reconstitution [ Time Frame: 1 year post-transplant ]
    Immune reconstitution: defined as absolute lymphocyte count (ALC) >1000x10e3/microL
  • Number of Participants With ACUTE GVHD [ Time Frame: Assessed weekly from Day 0 to day 100 ]
    Acute GVHD is graded by the method of Przepiorka D. et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD
  • Number of Participants With CHRONIC GVHD [ Time Frame: Assessed monthly from month 3 to month 12 ]
    Chronic GVHD is graded by NIH guidelines for chronic GVHD, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3 where 0 means no chronic GVHD, and 3 is the highest stage of chronic GVHD.
  • Event-free Survival [ Time Frame: up to 2 years post transplant ]
    Event-free survival is calculated from the date of transplant to the date of graft failure, disease recurrence or death from any cause.
Original Primary Outcome Measures  ICMJE
 (submitted: December 20, 2007)
  • Evaluate engraftment [ Time Frame: 30 days post-transplant ]
  • To evaluate the occurrence of transient and stable mixed hematopoietic chimerism (HC) after unrelated donor SCT and its effect on the recurrence of clinically measurable thalassemia. [ Time Frame: 2 years ]
  • To measure hematopoietic and immune reconstitution and assess the effects on infectious complications. [ Time Frame: 2 years ]
  • toxicities [ Time Frame: +100 days transplant ]
  • loss of chimerism [ Time Frame: 2 years post-transplant ]
  • GVHD [ Time Frame: 2 years post-transplant ]
  • morbidity and mortality post transplant [ Time Frame: 2 years ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Official Title  ICMJE Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia
Brief Summary

Patients have severe beta-thalassemia or one of the thalassemia variants. Thalassemia is a hereditary disease in which the bone marrow produces abnormal red blood cells that have a shorter life span than normal red blood cells. Because of that, the patient has chronically low red blood cell numbers (anemia) and need regular blood transfusions to help the patient feel better and to help prevent damage to important organs such as the heart. The following treatments are currently available to patients: lifelong blood transfusions and drugs that help remove iron from the body, and long-term antibiotics to prevent infections. These treatments are difficult for patients to take, and do not stop the effects of the disease.

Currently, the only treatment that may cure thalassemia is bone marrow or blood stem cell transplantation. Special blood or bone marrow cells from a healthy person might allow the bone marrow to create healthy cells, which will replace the abnormal red blood cells of thalassemia. There is a lot of experience using special blood or bone marrow cells from a healthy brother or sister who is the same HLA (immune) type. For patients who do not have such a donor in the family, an unrelated volunteer donor can be used. It is important for the patient to realize that this kind of transplant can have more problems than a transplant from a brother or sister.

Because we do not know the long-term effects of this treatment and because this type of transplant has not been used often for people with thalassemia, this is a research study. We hope, but cannot promise, that the transplanted marrow/stem cells will produce healthy cells and the patient will no longer have severe thalassemia.

Detailed Description

To be treated on this study, we will test the blood to check for viruses, including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant cannot be done because it would be too dangerous for the patient. Secondly, we will do a liver biopsy to determine if the liver has been damaged (which can happen from iron overload that develops after many transfusions). Too much liver damage could mean that the patient will have a higher risk to develop problems with the transplant.

To participate in this study, the patients also need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins in the neck or chest). Central lines are used to give intravenous medications (go directly into the vein) or to take blood samples without the patient having to endure frequent needle sticks. Before the treatment starts, we will remove a small amount of the bone marrow (back-up bone marrow) and store it. The reason for this is that if the donors bone marrow or blood stem cells do not grow properly after the transplant and the patients blood counts stay low, we can put the patients own bone marrow cells back into their body. This will help the blood counts to recover, but this means that the patient will also have thalassemia again.

To prepare the body for the transplant, the patients own blood forming system has to be destroyed and their immune system has to be weakened. To do this, they will be given high dose chemotherapy and medications that weaken their immune system (also called a conditioning treatment) for 9 days before the transplant. The main chemotherapy drugs used in the conditioning treatment are: cyclophosphamide, fludarabine and busulfan. The chemotherapy treatment will last 9 days. The patient will be admitted 10 days before the transplant to start a medicine to prevent seizures before they receive the first dose of busulfan since one of the side effects of busulfan is risk of seizures. First the patient will be given a drug called busulfan through the central line every 6 hours starting 9 days before transplant (called Day -9) until 6 days before transplant (called Day -6). Starting one day after receiving the last busulfan dose (Day -5), they will receive cyclophosphamide, fludarabine and Campath IH, which will all be given through the central line once a day for the next four days. Campath IH is a special type of protein called an antibody that works against certain types of blood cells. Also on Day -5, we will add a drug called MESNA. MESNA is used to decrease the side-effects caused by cyclophosphamide.

One day after the chemotherapy treatment is finished (Say -1) the patient will have a day to rest. On Say 0, the patient will receive the bone marrow/stem cells from the donor. Once in the bloodstream, the cells will go to the bone marrow and should begin to grow. To help prevent a problem call graft-versus-host disease (GVHD), the patient will receive a small dose of methotrexate on four different days after transplant. Another drug to help prevent GVHD, tacrolimus, will be started 2 days (Day -2) before the transplant and continued for approximately one year after the transplant. To tell whether the transplant has "taken" or "engrafted", we will take samples of blood two to three weeks after the transplant.

The patient will need to be in the hospital for at least 4 weeks after the transplant to make sure the transplant has engrafted. To find out how much the treatment has helped them and how much it might help other patients, we will do several routine lung, kidney, and liver tests, including liver biopsies, after the bone marrow/stem cell transplant. Additionally, we will be looking at the immune function. To do this, we will take 30 mL (2 tablespoonfuls) of blood every three months for the first year after transplant and then every 6 months during the second year after transplant. When possible, the blood that is taken will be taken through an existing IV line. However, at times drawing the blood will require another stick with a needle. The total amount of blood to be taken will not exceed 12 tablespoonfuls.

Because bone marrow/stem cell transplant from an unrelated volunteer donor is a new therapy for severe thalassemia and because problems may happen months afterward, the patient will need to have exams and blood tests done every few months during the first and second year following transplantation.

The patient may still need to use iron removing agents for some time after transplant or undergo blood-letting to get rid of the excess iron in the body. During that time, we will monitor the amount of iron in the body. Looking at the iron stored in the liver can most accurately tell us how much excess iron the patient has in the body. We will do liver biopsies once or twice per year if the patient is receiving iron chelation treatment after the transplant.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Thalassemia
Intervention  ICMJE
  • Drug: Busulfan

    4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg

    Days -9 through -6

    Other Name: Myleran
  • Drug: Fludarabine
    30mg/m2 Day -5 through Day -2
    Other Name: Fludara
  • Drug: Campath 1H
    Per institutional guidelines Days -5 through -2
    Other Name: Alemtuzumab
  • Drug: Cyclophosphamide
    50 mg/kg Days -5 through -2
    Other Name: Cytoxan
  • Drug: MESNA
    10 mg/kg x 5 Days -5 through -2
    Other Name: Mesnex
Study Arms  ICMJE Experimental: Bone Marrow or Stem Cell Infusion

Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H

Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.

Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.

Interventions:
  • Drug: Busulfan
  • Drug: Fludarabine
  • Drug: Campath 1H
  • Drug: Cyclophosphamide
  • Drug: MESNA
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: July 20, 2016)
10
Original Estimated Enrollment  ICMJE
 (submitted: December 20, 2007)
15
Actual Study Completion Date  ICMJE May 2016
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients with documented diagnosis of severe (transfusion-dependent) homozygous b0/+-thalassemia or severe variants of b0/+-thalassemia requiring chronic transfusion therapy and iron chelating agents, who fulfill the following conditions:

  1. Patient does not have an HLA genotype-identical donor available and has a 5/6 or 6/6 matched unrelated donor, or a 5/6 matched related donor available.
  2. Must be between 1 and 16 yrs of age (all Pesaro risk groups).
  3. Patients older than 17 yrs of age must be in Pesaro Risk Class 2 or lower (see Appendix B).
  4. Women of childbearing potential must have a negative pregnancy test.
  5. Documentation of compliance with iron chelation, absence or presence of hepatomegaly, and presence or absence of hepatic fibrosis prior to transplant (criteria for the Pesaro Risk Classification). This information will be obtained by history, physical exam and interpretation of liver biopsy results.
  6. Documentation of awareness of alternative treatment options.

Exclusion Criteria:

  1. Biopsy-proven chronic active hepatitis or fibrosis with portal bridging.
  2. Has previous history of malignancies.
  3. Creatinine clearance < 35 mL/min/1.73 M2.
  4. Severe cardiac dysfunction defined as shortening fraction < 25%.
  5. HIV infection.
  6. Inadequate intellectual capacity to give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).
  7. Be pregnant, lactating or unwilling to use appropriate birth control.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 64 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00578292
Other Study ID Numbers  ICMJE THALLO (H-14539)
H-14539 ( Other Identifier: Baylor College of Medicine IRB )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Tami D. John, Baylor College of Medicine
Study Sponsor  ICMJE Baylor College of Medicine
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Tami John, MD Baylor College of Medicine/Texas Children's Hospital
Study Director: Tami John, MD Baylor College of Medicine/Texas Children's Hospital
PRS Account Baylor College of Medicine
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP